/AVXL

Anavex Life Sciences Corp

AVXL

$2.62USD↓-1.50%-0.04 today

MARKET CAP

242.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$3 – $3

52W RANGE

$2

$10

AI Summary

Stalk

TrimMedium

AVXL remains entrenched in a Stage 4 decline with active lower highs and lower lows under declining EMAs. Both medium-term and long-term directional biases are bearish, and with price trading near support and below key EMAs, execution should be deferred until rallies into the declining 9/21 EMA resistance zone for a rejection-based trim entry.

↑Focus on novel Alzheimer’s and CNS drugs addresses unmet market need
↑PVG proxy campaign could install experienced management, aiding strategy execution
↓Deeply negative earnings yield and weak profitability factors raise financial concerns

Full analysis →

Buying

4

institutions

Selling

6

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	8.06 M	20.86 M	+446.01 K	-10.7%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUY	963.01 K	2.49 M	+206.22 K	+7.3%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	647.12 K	1.68 M	+-524.92 K	-53.4%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUYNEW	157.49 K	407.89 K	+157.49 K	+0.0%	0.00%
MM Millennium Management LLC Q2 2026	BUYNEW	60.48 K	156.65 K	+60.48 K	+0.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	46.77 K	121.59 K	+-3.40 K	-14.1%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	13.21 K	34.22 K	+-4.88 K	-38.4%	0.00%
RT Renaissance Technologies LLC Q2 2026	SELL	0.00	0.00	+-276.80 K	-100.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-69.64 K	-100.0%	0.00%
JH Janus Henderson Group Plc Q1 2026	SELL	0.00	0.00	+-37.00 K	-100.0%	0.00%